| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CERT |
| Uniprot No | Q9Y5P4-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 347-598aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWAGSMLH WPTSLPSGDA FSSVGTHRFV QKVEEMVQNH MTYSLQDVGG DANWQLVVEE GEMKVYRREV EENGIVLDPL KATHAVKGVT GHEVCNYFWN VDVRNDWETT IENFHVVETL ADNAIIIYQT HKRVWPASQR DVLYLSVIRK IPALTENDPE TWIVCNFSVD HDSAPLNNRC VRAKINVAMI CQTLVSPPEG NQEISRDNIL CKITYVANVN PGGWAPASVL RAVAKREYPK FLKRFTSYVQ EKTAGKPILF |
| 预测分子量 | 33 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CERT(Ceramide Transfer Protein)重组蛋白的示例参考文献(内容为模拟示例，实际文献需通过学术数据库检索)：
---
1. **文献名称**: *Structural insights into the lipid transfer mechanism of CERT protein*
**作者**: Kudo, N., et al.
**摘要**: 通过X射线晶体学解析CERT蛋白的START结构域与神经酰胺复合物的三维结构，揭示了其特异性结合和转运脂质的分子机制，为设计靶向CERT的抑制剂提供结构基础。
2. **文献名称**: *Functional characterization of recombinant CERT in intracellular ceramide trafficking*
**作者**: Hanada, K., & Kumagai, K.
**摘要**: 在大肠杆菌中成功表达重组CERT蛋白，并通过体外脂质体实验证明其介导神经酰胺从内质网到高尔基体的转运功能，证实PH结构域对膜定位的关键作用。
3. **文献名称**: *Development of a high-yield insect cell system for recombinant CERT production*
**作者**: Yamaji, T., et al.
**摘要**: 优化杆状病毒-昆虫细胞表达系统，实现重组CERT蛋白的高效可溶性表达，纯度达95%以上，适用于大规模生化研究与药物筛选。
4. **文献名称**: *CERT depletion alters cancer cell sensitivity to chemotherapeutic agents*
**作者**: Sasaki, H., & Nishijima, M.
**摘要**: 利用重组CERT蛋白及基因沉默技术，证明CERT通过调节鞘脂代谢影响肿瘤细胞对化疗药物的敏感性，提示其作为癌症治疗新靶点的潜力。
---
**注意**：以上文献信息为示例，非真实存在。建议通过PubMed、Web of Science等平台，以关键词“CERT protein recombinant”或“ceramide transfer protein structure/function”检索最新研究。真实文献可能包括：
- **Nature (2003)** 中Hanada团队首次克隆CERT基因的研究;
- **J. Cell Biol. (2007)** 关于CERT与细胞内脂筏形成的关系;
- **Cell Metabolism (2015)** 探讨CERT在代谢疾病中的作用。
**Background of CERT Recombinant Protein**
The Ceramide Transfer Protein (CERT), also known as StAR-related lipid transfer domain protein 11 (STARD11), is a key mediator of intracellular ceramide transport, primarily facilitating the non-vesicular transfer of ceramide from the endoplasmic reticulum (ER) to the Golgi apparatus. This process is critical for the synthesis of sphingomyelin, a major component of cell membranes. CERT contains a pleckstrin homology (PH) domain that binds phosphatidylinositol 4-phosphate (PI4P) in the Golgi, a START domain responsible for ceramide binding/transfer, and a FFAT motif that interacts with ER-resident VAP proteins, enabling ER-Golgi tethering.
Dysregulation of CERT is implicated in ceramide metabolism disorders, cancer progression, and neurodegenerative diseases. For instance, aberrant CERT activity may disrupt sphingolipid homeostasis, influencing cell survival, apoptosis, and chemoresistance. Recombinant CERT protein, produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), serves as a vital tool for studying these mechanisms. Its recombinant form enables *in vitro* analysis of lipid transfer kinetics, structural characterization (e.g., X-ray crystallography), and screening of therapeutic compounds targeting sphingolipid pathways.
Recent studies highlight CERT's potential as a drug target. Inhibitors blocking its ceramide-binding START domain or ER-Golgi interactions could modulate sphingolipid levels, offering therapeutic avenues for cancers or metabolic syndromes. Additionally, recombinant CERT aids in deciphering crosstalk between sphingolipids and cellular signaling networks, advancing our understanding of membrane biology and disease pathogenesis.
×
